Could a diabetes pill protect kidneys in lupus patients?

NCT ID NCT07323524

Recruiting now Disease control Sponsor: Brigham and Women's Hospital Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether dapagliflozin, a drug already used for diabetes and other kidney diseases, can help people with lupus nephritis. About 33 adults with active lupus kidney inflammation will receive either dapagliflozin or a placebo alongside their usual treatment. The main goal is to see if it's feasible to run a larger trial, not yet to prove the drug works.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Dapagliflozin
What this could lead to: If it works, this could point toward a new way to protect kidneys in people with lupus nephritis, reducing the risk of kidney failure.
What could go wrong: This is a small pilot study with only 33 people, so results may not apply broadly. It's testing feasibility, not yet proven to work, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LUPUS NEPHRITIS (LN) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

lupus nephritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LUPUS NEPHRITIS (LN)

Contacts and locations

Locations

Brigham and Women's Hospital
RECRUITING

Boston, Massachusetts, 02115, United States
Massachusetts General Hospital
RECRUITING

Boston, Massachusetts, 02114, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.